<DOC>
	<DOCNO>NCT01019317</DOCNO>
	<brief_summary>The goal clinical research study learn combination fludarabine cytarabine help control Acute Myelogenous Leukemia ( AML ) , High-Risk Myelodysplastic Syndrome ( MDS ) Chronic Myeloid Leukemia ( CML ) myeloid blast crisis . The safety drug combination also study .</brief_summary>
	<brief_title>Fludarabine Cytarabine Acute Myelogenous Leukemia ( AML ) High-Risk Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>The Study Drugs Fludarabine design make cancer cell less able repair damage DNA ( genetic material cell ) . This may increase likelihood cell die . Cytarabine design insert DNA stop DNA repair . Study Drug Administration : If find eligible take part study , receive fludarabine cytarabine . During cycle ( 4-6 week ) , receive study drug 5 day watch study staff 1 month . Induction ( Cycle 1 ) : For 3 , 4 , 5 day Days 1-5 Cycle 1 , receive fludarabine vein 15-30 minute 2 time day ( every 12 hour ) . For 3 , 4 , 5 day Days 1-5 Cycle 1 , receive cytarabine vein 2 hour 2 time day ( every 12 hour ) . If cancer completely respond Cycle 1 , may repeat induction ( Cycle 1 ) . If cancer completely respond , begin consolidation cycle . Consolidation ( Cycles 2-7 ) : For 3 4 day Days 1-4 Cycles 2-7 , receive fludarabine vein 15-30 minute 2 time day ( every 12 hour ) . For 3 4 day Days 1-4 Cycles 2-7 , receive cytarabine vein 2 hour 2 time day ( every 12 hour ) . Study Visits : At study visit , ask side effect may drug may take . During Induction Therapy ( Cycle 1 ) : - Blood ( 2 tablespoon ) draw routine test every 3-7 day . - About Day 28 , may bone marrow aspirate check status disease . During Consolidation Therapy ( Cycles 2-7 ) : - Blood ( 2 tablespoon ) draw routine test every 1-2 week . - You bone marrow aspirate every 2-3 cycle check status disease . Length Study : You able receive study drug 8 month . You take study treatment intolerable side effect , disease get bad , study doctor think best interest . Long-Term Follow-Up : Every 3 month 2 year study treatment , call ask feeling , side effect may , another drug may take . Supportive Care : Please talk doctor drug take study . This investigational study . Cytarabine FDA approve commercially available frontline ( first ) treatment AML . Fludarabine FDA approve commercially available treatment CLL . The combination 2 drug treat AML , MDS , CML myeloid blast crisis investigational . Up 150 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Sign Internal Review Board ( IRB ) approve informed consent document . 2 . Age &gt; /= 12 year . 3 . Diagnosis AML [ acute promyelocytic leukemia ( APL ) ] refractory/relapsed disease . Patients newly diagnose AML eligible candidate intensive chemotherapy . Patients highrisk ( intermediate2 high IPSS &gt; /=10 % blast ) MDS also eligible . Patients chronic myeloid leukemia ( CML ) blast crisis eligible well . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 3 study entry . 5 . Organ function define ( unless due leukemia ) : i. Serum creatinine &lt; /= 3 mg/dL ; ii . Total bilirubin &lt; /= 3 mg/dL ; iii . Alanine aminotransferase ( ALT ) ( Serum Glutamic Pyruvate Transaminase ( SGPT ) ) &lt; /= 5 time upper limit normal ( ULN ) &lt; /= 10 time ULN related disease . 6 . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test within 7 day . Men must agree father child agree use condom partner child bear potential . 1 . Pregnant breastfeeding female . 2 . Diagnosis acute promyelocytic leukemia ( M3 ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>High-Risk Myelodysplastic Syndrome</keyword>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Blast crisis</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine arabinosine hydrochloride</keyword>
	<keyword>Arabinosine Hydrochloride</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Gemtuzumab Ozogamicin</keyword>
	<keyword>Mylotarg</keyword>
</DOC>